Answers are grounded in this paper and cite their sources.
INTRODUCTION: Blinatumomab, a bispecific T-cell engager, requires the activity of CD3+ T-cells for tumor lysis. This pooled analysis aimed to re-examine baseline T regulatory cells (Tregs) as a biomarker of blinatumomab efficacy across multiple clinical trials and provide insights into peripheral T-cell dynamics during blinatumomab therapy in hematological malignancies. METHODS: Tregs and peripheral T-cells were enumerated by fluorescence-activated cell sorting and were statistically evaluated using the Wilcoxon rank-sum test and linear mixed effect modeling, respectively. RESULTS: Comparable baseline percentages of Tregs were observed in responders and non-responders of blinatumomab treatment (N = 325) in adults with leukemia or lymphoma. Peripheral T-cell count recovery occurred early during blinatumomab dosing, and before blinatumomab-free interval in patients (N = 233) from 4 clinical trials. CONCLUSION: The pooled analysis revealed that baseline Treg levels do not serve as a predictive marker for blinatumomab response and that there is rapid peripheral T-cell recovery following blinatumomab dosing. These results suggest that patients with varying levels of Tregs can benefit from blinatumomab treatment and that blinatumomab-free intervals of 7 days may suffice in blinatumomab treatment regimens.
No takes yet. Share an insight, caveat, or question.
Katlinskaya et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: